集中约谈会在亳州召开

Core Viewpoint - The provincial drug regulatory authority held a meeting to address the quality management of high-risk traditional Chinese medicine (TCM) decoction pieces, emphasizing the need for strict regulatory compliance and quality assurance measures [1][2]. Group 1: Meeting Overview - A concentrated meeting was held in Bozhou with representatives from 34 high-risk TCM decoction piece production enterprises [1]. - The provincial drug regulatory authority announced a notification regarding enhanced supervision of high-risk TCM decoction piece manufacturers for 2026 [1]. Group 2: Quality Safety Analysis - The meeting analyzed the overall quality safety situation of TCM decoction pieces in the province, highlighting various uncertainties affecting quality [2]. - Emphasis was placed on the importance of legal compliance and the rejection of illegal practices such as document forgery and substandard production [2]. Group 3: Risk Management and Quality Improvement - The need for strict implementation of primary responsibilities and continuous risk awareness was stressed, with a focus on identifying and addressing potential hazards [2]. - The meeting called for the enhancement of source control, adherence to production norms, and the establishment of a comprehensive quality management system to achieve high-quality development [2].